Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Varian's Trilogy products:

This article was originally published in Clinica

Executive Summary

Varian Medical Systems has gained US FDA 510(k) market clearance to use its high-energy, "ultra-precise" Trilogy linear accelerators on an expanded range of medical conditions. The clearance also marks the introduction of Varian's new Trilogy Tx image-guided radiosurgery (IGRS) model, designed specifically for surgeons. Physicians can now provide Trilogy treatments for functional lesions such as trigeminal neuralgia and other non-cancerous conditions, said the Palo Alto, California firm. The prior FDA clearance for the Trilogy device was limited to benign and malignant cancers, and arteriovenous malformations.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT052033

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel